New treatment for advanced ovarian cancer using a small molecule inhibitor
Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients
This study is testing a new drug designed to help treat advanced ovarian cancer by targeting a specific part of cancer cells, and it’s for patients looking for better options since current treatments can have tough side effects.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Up Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Frederick, UNITED STATES) |
| Project ID | NIH-10916490 on NIH RePORTER |
What this research studies
This research focuses on developing a novel small molecule inhibitor targeting RPN13 to treat advanced ovarian cancer, a condition that currently has limited effective therapies. The approach involves creating a drug that can effectively penetrate solid tumors and overcome the limitations of existing proteasome inhibitors, which often cause severe side effects. By targeting the proteasome's function in cancer cells, the treatment aims to reduce the accumulation of harmful proteins that contribute to cancer progression. Patients may have the opportunity to participate in trials assessing the safety and efficacy of this new treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced epithelial ovarian cancer who have not responded well to existing therapies.
Not a fit: Patients with early-stage ovarian cancer or those who have not been diagnosed with ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment option for patients with advanced ovarian cancer.
How similar studies have performed: While proteasome inhibitors have shown success in treating liquid tumors, this approach is novel for solid tumors like ovarian cancer and has not been extensively tested.
Where this research is happening
Frederick, UNITED STATES
- Up Therapeutics, INC. — Frederick, United States (Active)
Researchers
- Principal investigator: Anchoori, Ravi Kumar — Up Therapeutics, INC.
- Study coordinator: Anchoori, Ravi Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.